The aim of this study is to determine whether topical crisaborole improves hair growth in alopecia areata.
Each individual will be enrolled in the study for 24 weeks. Following a 28 days screening period, eligible subjects will be randomized in a 1:1 ratio to receive either crisaborole 2% ointment or matching placebo for 12 weeks. The primary endpoint is assessed at week 12. At the week 12 visit, all subjects will enter the open label treatment period where they will all receive crisaborole 2% ointment for an additional 12 weeks, with the last study visit taking place on week 24.
| Condition | Hair Loss, Male Pattern Baldness, areata alopecia, Alopecia Areata, Alopecia |
|---|---|
| Treatment | Crisaborole Topical Ointment, Placebo Topical Ointment |
| Clinical Study Identifier | NCT04299503 |
| Sponsor | Tufts Medical Center |
| Last Modified on | 5 March 2022 |
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer
Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!
No annotations made yet
Congrats! You have your own personal workspace now.